{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:09:45Z","timestamp":1790143785777,"version":"4.0.1"},"reference-count":59,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:p>For any biological response, transmission of extracellular signals to the nucleus is required for DNA transcription and gene expression. In that respect, cytokines\/chemokines are well-known inflammatory agents which play a critical role in signalling pathways by activating the Janus kinase\u2013signal transducers and activators of transcription (JAK-STAT) signalling proteins (Janus kinase\u2013signal transducers and activators of transcription) which are a group of intracellular kinase molecules. Cytokines are a category of small proteins (\u223c5\u201325 kDa) that play a major role in cell signalling and are major drivers of an autoimmune response. Here we will discuss the role of Janus kinase\u2013signal transducers and activators of transcription kinase cascades in the inflammatory-proliferative cascades of autoimmune disease and about the recent progress in the development of oral synthetic Janus kinase inhibitors (JAKi) and their therapeutic efficacies in dermatologic and systemic autoimmune diseases. <\/jats:p>\n<jats:p>Therapeutic efficacy of Janus kinase inhibitors is now well established in the treatment of array of autoimmune and inflammatory disease: spondylarthritis with a special focus on psoriatic arthritis (PsA) and its dermatologic manifestations (psoriasis) and ankylosing spondylitis (AS), atopic dermatitis (AD), alopecia areata (AA), rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). <\/jats:p>\n<jats:p>In addition to the first-generation Janus kinase inhibitors several new-generation Janus kinase inhibitors are currently being evaluated. It is expected that these Janus kinase inhibitors likely have higher potency and less adverse effects as compared to their predecessors. Here we have discussed: (1) the functional significance of the Janus kinase\u2013signal transducers and activators of transcription kinase cascades in the inflammatory-proliferative processes of autoimmune diseases and its cellular\/molecular mechanisms and (2) progress in the development of oral synthetic Janus kinase inhibitors and their therapeutic efficacies in several systemic and cutaneous autoimmune diseases. <\/jats:p>","DOI":"10.25259\/ijdvl_1152_2022","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T10:16:48Z","timestamp":1690193808000},"page":"691-699","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["JAK-STAT inhibitors in Immune mediated diseases: An Overview"],"prefix":"10.25259","volume":"89","author":[{"given":"Ruchi Jayesh","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Medicine, School of Medicine, University of California Davis, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Department of Veterans Affairs, VA Sacramento Medical Center, Northern California Health Care, California, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smriti","family":"Raychaudhuri","sequence":"additional","affiliation":[{"name":"Department of Veterans Affairs, VA Sacramento Medical Center, Northern California Health Care, California, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siba P.","family":"Raychaudhuri","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, University of California Davis, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"10.25259\/IJDVL_1152_2022\/ref-1","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/BOR.0000000000000810","article-title":"Janus kinase-signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition","volume":"33","author":"Raychaudhuri","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"10.25259\/IJDVL_1152_2022\/ref-2","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1002\/art.41906","article-title":"A decade of JAK inhibitors: what have we learned and what may be the future?","volume":"73","author":"Liu","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_1152_2022\/ref-3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/BOR.0000000000000399","article-title":"Janus kinase\/signal transducer and activator of transcription pathways in spondyloarthritis","volume":"29","author":"Raychaudhuri","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.25259\/IJDVL_1152_2022\/ref-4","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1038\/jid.2008.38","article-title":"FR255734, a humanized, Fc-silent, anti-CD28 antibody improves psoriasis in the SCID mouse-psoriasis xenograft model","volume":"128","author":"Raychaudhuri","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_1152_2022\/ref-5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coi.2019.02.002","article-title":"Studying interactions between dendritic cells and T cells in vivo","volume":"58","author":"Chudnovskiy","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"10.25259\/IJDVL_1152_2022\/ref-6","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1136\/annrheumdis-2019-216658","article-title":"Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells","volume":"81","author":"Raychaudhuri","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_1152_2022\/ref-7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13075-017-1249-5","article-title":"Mechanistic rationales for targeting interleukin-17A in spondyloarthritis","volume":"19","author":"Raychaudhuri","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.25259\/IJDVL_1152_2022\/ref-8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cyto.2018.08.001","article-title":"IL-9 receptor: Regulatory role on FLS and pannus formation","volume":"111","author":"Raychaudhuri","year":"2018","journal-title":"Cytokine"},{"key":"10.25259\/IJDVL_1152_2022\/ref-9","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.cell.2020.04.052","article-title":"SnapShot: Jak-STAT Signaling II","volume":"25;181","author":"Villarino","year":"2020","journal-title":"Cell"},{"key":"10.25259\/IJDVL_1152_2022\/ref-10","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","article-title":"Janus kinases to jakinibs: from basic insights to clinical practice","volume":"58(Suppl 1)","author":"Gadina","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.25259\/IJDVL_1152_2022\/ref-11","doi-asserted-by":"publisher","first-page":"e001374","DOI":"10.1136\/rmdopen-2020-001374","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research","volume":"6","author":"Kerschbaumer","year":"2020","journal-title":"RMD Open"},{"key":"10.25259\/IJDVL_1152_2022\/ref-12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_1152_2022\/ref-13","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus Kinase family in autoimmune skin diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_1152_2022\/ref-14","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jaci.2020.10.022","article-title":"The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases","volume":"147","author":"Damsky","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.25259\/IJDVL_1152_2022\/ref-15","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"10.25259\/IJDVL_1152_2022\/ref-16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cyto.2015.12.020","article-title":"IL-9, a local growth factor for synovial T cells in inflammatory arthritis","volume":"79","author":"Kundu-Raychaudhuri","year":"2016","journal-title":"Cytokine"},{"key":"10.25259\/IJDVL_1152_2022\/ref-17","first-page":"521","article-title":"Drugs. JAK-STAT signaling as a target for inflammatory and autoimmune diseases","volume":"77","author":"Banerjee","year":"2017","journal-title":"Current and Future Prospects"},{"key":"10.25259\/IJDVL_1152_2022\/ref-18","article-title":"Blockade of the JAK\/STAT pathway inhibits inflammation and bone formation in two murine models of spondyloarthritis","volume":"70(Suppl. 10)","author":"Maeda","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_1152_2022\/ref-19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1126\/scitranslmed.aag1974","article-title":"Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity","volume":"8","author":"Dendrou","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.25259\/IJDVL_1152_2022\/ref-20","doi-asserted-by":"publisher","first-page":"15645","DOI":"10.1038\/s41598-018-34026-1","article-title":"Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases","volume":"8","author":"Hammitzsch","year":"2018","journal-title":"Sci Rep"},{"key":"10.25259\/IJDVL_1152_2022\/ref-21","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1172\/JCI126567","article-title":"TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis","volume":"130","author":"Gracey","year":"2020","journal-title":"J Clin Invest"},{"key":"10.25259\/IJDVL_1152_2022\/ref-22","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.clim.2010.05.003","article-title":"Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitis in Chinese Han population","volume":"136","author":"Chen","year":"2010","journal-title":"Clin Immunol"},{"key":"10.25259\/IJDVL_1152_2022\/ref-23","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ajhg.2012.02.020","article-title":"Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci","volume":"90","author":"Ellinghaus","year":"2012","journal-title":"Am J Hum Gen"},{"key":"10.25259\/IJDVL_1152_2022\/ref-24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1744-313X.2012.01084.x","article-title":"Investigation of JAK2, STAT3 and CCR6 polymorphisms and their gene-gene interactions in inflammatory bowel disease","volume":"39","author":"Polgar","year":"2012","journal-title":"Int J Immunogenet"},{"key":"10.25259\/IJDVL_1152_2022\/ref-25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.0105-2896.2005.00220.x","article-title":"JAK3, severe combined immunodeficiency, and a new class of immunosuppressive drugs","volume":"203","author":"Pesu","year":"2005","journal-title":"Immunol Rev"},{"key":"10.25259\/IJDVL_1152_2022\/ref-26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J Inflamm (Lond)"},{"key":"10.25259\/IJDVL_1152_2022\/ref-27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jdermsci.2011.11.011","article-title":"Podoplanin expression in wound and hyperproliferative psoriatic epidermis: Regulation by TGF\u03b2 and STAT3 activating cytokines, IFN\u03b3, IL6, and IL22","volume":"65","author":"Honma","year":"2012","journal-title":"J Dermatol Sci"},{"key":"10.25259\/IJDVL_1152_2022\/ref-28","first-page":"440","article-title":"The JAK inhibitor tofacitinib suppresses synovial JAK1STAT signalling in rheumatoid arthritis","volume":"71","author":"Boyle","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_1152_2022\/ref-29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","article-title":"Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors","volume":"75","author":"Gao","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_1152_2022\/ref-30","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1136\/annrheumdis-2016-211046","article-title":"Regulatory role of the JAK STAT kinase signaling system on the IL-23\/IL-17 cytokine axis in psoriatic arthritis","volume":"76","author":"Raychaudhuri","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_1152_2022\/ref-31","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1158\/1078-0432.CCR-12-0653","article-title":"US Food and Drug Administration Approval: Ruxolitinib for the treatment of patients with intermediate and high risk Myelofibrosis","volume":"18","author":"Deisseroth","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.25259\/IJDVL_1152_2022\/ref-32","first-page":"15","article-title":"Selective JAKinibs:Prospects in inflammatory and autoimmune diseases","volume":"33","author":"T Virtanen","year":"2019","journal-title":"Bio Drugs"},{"key":"10.25259\/IJDVL_1152_2022\/ref-33","first-page":"431","article-title":"The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders","volume":"27","author":"Furumoto","year":"2013","journal-title":"Bio Drugs"},{"key":"10.25259\/IJDVL_1152_2022\/ref-34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.25259\/IJDVL_1152_2022\/ref-35","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050","volume":"184","author":"Fridman","year":"2010","journal-title":"J Immunol"},{"key":"10.25259\/IJDVL_1152_2022\/ref-36","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.25259\/IJDVL_1152_2022\/ref-37","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_1152_2022\/ref-38","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years:integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_1152_2022\/ref-39","first-page":"638","article-title":"FRI0123: Safety profile of Baricitinib for the treatment of Rheumatoid Arthritis up to 8.4 years: an updated integrated safety analysis","volume":"79(Suppl. 1)","author":"Genovese","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_1152_2022\/ref-40","first-page":"315","article-title":"THU0187: Safety profile of Upadacitinib up to 3 years of exposure in patients with Rheumatoid Arthritis","volume":"79(Suppl. 1)","author":"Cohen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_1152_2022\/ref-41","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_1152_2022\/ref-42","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: Clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_1152_2022\/ref-43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5\u2005years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.25259\/IJDVL_1152_2022\/ref-44","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_1152_2022\/ref-45","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/acr.23769","article-title":"Risk for herpes zoster in Tofacitinib-treated glucocorticoids","volume":"71","author":"Curtis","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.25259\/IJDVL_1152_2022\/ref-46","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_1152_2022\/ref-47","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2665-9913(20)30032-1","article-title":"Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis","volume":"2","author":"Genovese","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.25259\/IJDVL_1152_2022\/ref-48","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/acr.24007","article-title":"Efficacy and safety of long-term bricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate","volume":"72","author":"Fleischmann","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.25259\/IJDVL_1152_2022\/ref-49","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_1152_2022\/ref-50","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00393-020-00750-1","article-title":"Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis","volume":"79","author":"Lee","year":"2020","journal-title":"Z Rheumatol"},{"key":"10.25259\/IJDVL_1152_2022\/ref-51","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_1152_2022\/ref-52","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: The FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"10.25259\/IJDVL_1152_2022\/ref-53","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)","volume":"78","author":"Tanaka","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_1152_2022\/ref-54","doi-asserted-by":"publisher","first-page":"R158","DOI":"10.1186\/ar4673","article-title":"Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials","volume":"16","author":"Isaacs","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.25259\/IJDVL_1152_2022\/ref-55","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/art.40054","article-title":"Peficitinib, a JAK Inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_1152_2022\/ref-56","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial","volume":"80","author":"Westhovens","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_1152_2022\/ref-57","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_1152_2022\/ref-58","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_1152_2022\/ref-59","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/art.40798","article-title":"Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study","volume":"71","author":"Desai","year":"2019","journal-title":"Arthritis Rheumatol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/jak-stat-inhibitors-in-immune-mediated-diseases-an-overview\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/jak-stat-inhibitors-in-immune-mediated-diseases-an-overview\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T04:34:05Z","timestamp":1693197245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/jak-stat-inhibitors-in-immune-mediated-diseases-an-overview\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":59,"alternative-id":["10.25259\/IJDVL_1152_2022"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_1152_2022","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"article-number":"691"}}